The global pharmaceutical industry experienced a 63% drop in company filings mentions of cloud in Q2 2024 compared with the previous quarter, with the highest share accounted for by Biogen with 150% year-on-year increase, according to GlobalData’s analysis of over 72 pharmaceutical company filings. GlobalData’s Pharma: Filings Trends & Signals Q2 2024 report delves into earnings call transcripts and quarterly reports within the pharmaceuticals industry, extracting trends, signals, and comparative data to help businesses assess their performance, identify competitive intelligence, evaluate risks, and gain a comprehensive understanding of key industry events. Buy the report here.
Notably, cloud was one of the most frequently referenced themes in Q2 2024, ranking highest in terms of mentions, ahead of connected care and cryptocurrencies, according to GlobalData.
Of the top leading companies in the pharmaceutical industry, Biogen had the greatest increase in references for cloud in Q2 2024, compared with the previous quarter. GlobalData identified five cloud-related sentences in the company's filings - 0.2% of all sentences - and an increase of 150% in Q2 2024 compared with Q2 2023. Pfizer’s mentions of cloud dropped by 33% to 2 and Royalty Pharma Plc’s by 100% to 2.
GlobalData’s Company Filings Analytics also applies sentiment weight to reference sentences, based on whether the sentences are positive, negative, or neutral. Starting at 100 in 2020, an index over 100 is more positive. The overall index for cloud in Q2 2024 was 61.
For further understanding of GlobalData's Pharma: Filings Trends & Signals Q2 2024, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.